Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07028632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Phase 1/2 to Phase 2 Study description revisedv2 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
Trial Details
NCT Number NCT07028632
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Parkinson Disease (PD)
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov